Funds will be used to support the advancement of COUR™s Myasthenia Gravis (MG) and Type 1 Diabetes (T1D) product candidates into Phase 2a clinical trialsParticipating investors include Roche Venture...
CHICAGO, July 19, 2023 /PRNewswire/ -- COUR Pharmaceuticals, a clinical-stage biotechnology company developing novel immune-modifying nanoparticles designed to reprogram the immune system, today announced the appointment of Dannielle Appelhans as Chief Operating Officer, effective immediately. In this role, Ms. Appelhans will oversee and execute the Company's research and development, technical development, technical operations, and quality as well as be a significant contributor to corporate strategy and other business operations.
COUR Pharmaceuticals Announces Biotechnology Industry Veteran Robert F. Carey Joins Board of Directors as Lead Independent Director
COUR Pharmaceuticals, Boehringer Ingelheim, Genentech, GSK, and Idorsia Pharmaceuticals to Keynote at Veeva Commercial Summit, Europe
CHICAGO, Oct. 25, 2022 /PRNewswire/ -- COUR Pharmaceuticals, a clinical-stage biotechnology company developing novel immune-modifying nanoparticles designed to reprogram the immune system for the treatment of autoimmune disorders (COUR NanoParticles or CNPs), today announced that the U.S. Food and Drug Administration has cleared an Investigational New Drug (IND) application to initiate a Phase 1b/2a proof-of-concept study of COUR's investigational therapy, CNP-106. The therapy is designed to treat the underlying autoimmune causes of myasthenia gravis (MG) through antigen-specific tolerance induced by CNP-106.
CHICAGO, Feb. 28, 2022 /PRNewswire/ -- COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders, today announced the appointment of Brian C. Bock as the Company's new Chief Financial Officer (CFO). Mr. Bock will draw on his more than 20 years of financial management experience in life science operations and investment banking to support the Company's long-term growth strategy.
CHICAGO, Jan. 10, 2022 /PRNewswire/ -- COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders, today announced the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to the Company's investigational therapy CNP-104 for the treatment of Primary Biliary Cholangitis. CNP-104 aims to reprogram the immune system to address autoimmune causes of PBC.
CHICAGO, Oct. 19, 2021 /PRNewswire/ -- COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced that the first patient has been dosed in the Company's first-in-human proof-of-concept (Phase 1b/2a) of its lead candidate, CNP-201, for the treatment of peanut allergy. The trial will evaluate the safety and efficacy of CNP-201 in people ages 16 to 55 with peanut allergy and is led by Kari Nadeau, M.D., Ph.D., Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University.
CHICAGO, Oct. 4, 2021 /PRNewswire/ -- COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders today announced the U.S. FDA accepted an investigational new drug application (IND) for a proof-of-concept study of COUR's investigatory therapy CNP-104 to address autoimmune causes of Primary Biliary Cholangitis (PBC).
CHICAGO, Sept. 16, 2021 /PRNewswire/ -- COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for evaluation of COUR's CNP-201 in a proof-of-concept (Phase 1 / 2) study in people who are allergic to peanuts.